Amsterdam, The Netherlands 10/22/07—Avantium will list on the Euronext Amsterdam stock exchange by the end of the year. Avantium provides catalysis and crystallization research services and products utilizing high-throughput chemical experimentation. The company is also developing biofuels, biobased products and novel crystal forms of drugs. In 2006, Avantium’s revenues increased 40% to €13.5 million ($16.9 million), and it was cash flow and earnings positive.